Find trials
Search tips

Tau PET Outcomes with Anti-amyloid Immunotherapies

Overview

About this study

The purpose of this study is to evaluate change in tau PET in patients receiving anti-amyloid immunotherapies.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age 50-90 years.
  • Male or female.
  • Mild cognitive impairment due to AD or mild AD.
  • Amyloid positive via CSF or PET.
  • Meets other eligibility criteria for anti-amyloid immunotherapy.
  • Subject or delegate provides informed consent.
  •  

Exclusion Criteria

  • Subjects unable to lie down without moving for 10 minutes.
  • Women who are pregnant or cannot stop breast feeding for 24 hours.
  • Claustrophobic patients unable to tolerate the scans (no sedation can be offered).
  • Prolonged QT interval (as demonstrated by ECG test)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/18/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Petrice Cogswell, M.D., Ph.D.

Contact us for the latest status

Contact information:

Casey McAdam

McAdam.Casey@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20576070

Mayo Clinic Footer